

Institutional review board statement: Research ethics approval was obtained from the local research ethics committee (*Alberta Cancer Research Ethics Committee*).

Corresponding Author

Nawaid Usmani

Signature:  Date: November 16, 2018

15 September 2008

Dr. Nawaid Usmani
Alberta Cancer Board
Department of Radiation Oncology
Cross Cancer Institute

Dear Dr. Usmani:

RE: 24152: Biological Investigations in Active Surveillance (BIAS)

On behalf of the Research Ethics Board (REB, full board) meeting of 9 September 2008, I would like to thank you for presenting the above-mentioned study at our meeting.


The REB had no concerns regarding the scientific and ethical relevance of the study, but recommended several editorial changes to the consent forms. Copies are attached for your perusal.

Please note that the final REB approval letter for this study will be released upon receipt of:

- A satisfactory review of the revised consent forms

Please forward this and/or any questions you may have to the ACB Research Administration Office at 780-643-4568 or 780-643-4572.

Sincerely,



Scott North, M.D.
Chair, Research Ethics Board

/jg

PC: Juliette Jordan
Clinical Research Unit, CCI

Attachments



**Alberta Health
Services**
Alberta Cancer Board

1500 Sun Life Place, 10123 99 Street Edmonton, Alberta T5J 3H1

12 March 2009

Dr. Nawaid Usmani
Alberta Health Services - Alberta Cancer Board
Department of Radiation Oncology
Cross Cancer Institute

Dear Dr. Usmani:

RE: 24152: IGAR 2008 I 19- Biological Investigations in Active Surveillance (BIAS)

Thank you for your letter dated 4 March 2009 together with a revised main consent form and revised banking of tumour sample for future research consent form both with version dates of 2 March 2009 in reference to the above named study.

On behalf of the Research Ethics Board (REB) I acknowledge receipt of these documents and have reviewed them. Approval is granted for the revised main consent form and revised banking of tumour sample for future research consent form both with version dates of 2 March 2009. It is noted that the revisions were administrative in nature only.

Sincerely,

Suzanne Marney
Research Ethics Coordinator

/sm

PC: Juliette Jordan
Clinical Research Unit, CCI

15 June 2009

Dr. Nawaid Usmani
Alberta Health Services
Department of Radiation Oncology
Cross Cancer Institute

Dear Dr. Usmani:

RE: 24152: IGAR 2008 I 19- Biological Investigations in Active Surveillance (BIAS)

Thank you for your letter dated 25 May 2009 together with the following in reference to the above named study:


- Revised protocol dated 25 May 2009
- Revised main consent form dated 4 June 2009
- Revised banking consent form dated 4 June 2009

On behalf of the Alberta Cancer Research Ethics Committee (ACREC) I acknowledge receipt of these documents and have reviewed them. Approval is granted for the following:

- Revised protocol dated 25 May 2009
- Revised main consent form dated 4 June 2009
- Revised banking consent form dated 4 June 2009

If there are any other changes to the protocol or consent form during the year, or if any adverse reactions to the treatment are found, the ACREC requests that you forward a letter describing the changes/reactions, together with an updated consent form **to the Research Administration Office**.

Sincerely,



Scott North, M.D.
Chair, Alberta Cancer Research Ethics Committee

/sm

PC: Juliette Jordan
Clinical Research Unit, CCI

Alberta Cancer Research Ethics Committee 1500 – 10123 99 Street Edmonton AB T5J 3H1
Tel: (780) 643-4568/ (780) 643-4572 Fax: (780) 643-4557 Email: researchethics@cancerboard.ab.ca

1. The membership of this Research Ethics Committee complies with the membership requirements for Research Ethics Boards defined in Part C Division 5 of the *Food and Drug Regulations*;
2. This Research Ethics Committee carries out its functions in a manner consistent with Good Clinical Practices; and
3. This Research Ethics Committee has reviewed and approved the clinical trial protocol and informed consent form for the trial which is to be conducted by the qualified investigator named above at the specified clinical trial site(s). This approval and the views of this Research Ethics Committee have been documented in writing.